Drug Profile
Research programme: coeliac disease therapies - Numerate/Stanford University
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Numerate; Stanford University
- Class Small molecules
- Mechanism of Action Transglutaminase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Coeliac disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Coeliac disease in USA
- 19 Mar 2009 Numerate receives Small Business Technology Transfer (STTR) Phase 1 grant from National Institutes of Health for research collaboration with Stanford University for development of transglutaminase 2 inhibitors in Coeliac disease
- 19 Mar 2009 Early research in Coeliac disease in USA (unspecified route)